vs
CATHAY GENERAL BANCORP（CATY）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
CATHAY GENERAL BANCORP的季度营收约是Orthofix Medical Inc.的1.0倍（$222.8M vs $219.9M），CATHAY GENERAL BANCORP净利率更高（653.4% vs -1.0%，领先654.4%），CATHAY GENERAL BANCORP同比增速更快（19.5% vs 2.0%），CATHAY GENERAL BANCORP自由现金流更多（$363.7M vs $16.8M），过去两年CATHAY GENERAL BANCORP的营收复合增速更高（12.8% vs 8.0%）
国泰万通金控是总部位于美国的银行控股公司，旗下运营国泰银行，面向亚裔社区、中小企业提供个人及商业存贷款、财富管理等金融服务，业务覆盖加州、纽约、得州等美国多州及部分亚洲市场。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CATY vs OFIX — 直观对比
营收规模更大
CATY
是对方的1.0倍
$219.9M
营收增速更快
CATY
高出17.5%
2.0%
净利率更高
CATY
高出654.4%
-1.0%
自由现金流更多
CATY
多$346.8M
$16.8M
两年增速更快
CATY
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $222.8M | $219.9M |
| 净利润 | $90.5M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 50.9% | 0.2% |
| 净利率 | 653.4% | -1.0% |
| 营收同比 | 19.5% | 2.0% |
| 净利润同比 | 12.9% | 92.4% |
| 每股收益（稀释后） | $1.33 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CATYOFIX
| Q4 25 | $222.8M | $219.9M | ||
| Q3 25 | $210.6M | $205.6M | ||
| Q2 25 | $196.6M | $203.1M | ||
| Q1 25 | $187.8M | $193.6M | ||
| Q4 24 | $186.5M | $215.7M | ||
| Q3 24 | $189.5M | $196.6M | ||
| Q2 24 | $178.5M | $198.6M | ||
| Q1 24 | $175.2M | $188.6M |
净利润CATYOFIX
| Q4 25 | $90.5M | $-2.2M | ||
| Q3 25 | $77.7M | $-22.8M | ||
| Q2 25 | $77.5M | $-14.1M | ||
| Q1 25 | $69.5M | $-53.1M | ||
| Q4 24 | $80.2M | $-29.1M | ||
| Q3 24 | $67.5M | $-27.4M | ||
| Q2 24 | $66.8M | $-33.4M | ||
| Q1 24 | $71.4M | $-36.0M |
毛利率CATYOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CATYOFIX
| Q4 25 | 50.9% | 0.2% | ||
| Q3 25 | 44.5% | -8.3% | ||
| Q2 25 | 49.0% | -7.9% | ||
| Q1 25 | 46.1% | -25.2% | ||
| Q4 24 | 46.5% | -5.3% | ||
| Q3 24 | 41.2% | -9.6% | ||
| Q2 24 | 40.7% | -12.5% | ||
| Q1 24 | 45.7% | -15.6% |
净利率CATYOFIX
| Q4 25 | 653.4% | -1.0% | ||
| Q3 25 | 36.9% | -11.1% | ||
| Q2 25 | 39.4% | -6.9% | ||
| Q1 25 | 37.0% | -27.4% | ||
| Q4 24 | 587.9% | -13.5% | ||
| Q3 24 | 35.6% | -13.9% | ||
| Q2 24 | 37.4% | -16.8% | ||
| Q1 24 | 40.8% | -19.1% |
每股收益（稀释后）CATYOFIX
| Q4 25 | $1.33 | $-0.05 | ||
| Q3 25 | $1.13 | $-0.57 | ||
| Q2 25 | $1.10 | $-0.36 | ||
| Q1 25 | $0.98 | $-1.35 | ||
| Q4 24 | $1.11 | $-0.76 | ||
| Q3 24 | $0.94 | $-0.71 | ||
| Q2 24 | $0.92 | $-0.88 | ||
| Q1 24 | $0.98 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $119.1M | — |
| 股东权益账面价值 | $2.9B | $450.0M |
| 总资产 | $24.2B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.04× | — |
8季度趋势，按日历期对齐
现金及短期投资CATYOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务CATYOFIX
| Q4 25 | $119.1M | — | ||
| Q3 25 | $119.1M | $157.2M | ||
| Q2 25 | $119.1M | $157.0M | ||
| Q1 25 | $119.1M | $156.9M | ||
| Q4 24 | $119.1M | $157.0M | ||
| Q3 24 | $119.1M | $118.5M | ||
| Q2 24 | $119.1M | $118.0M | ||
| Q1 24 | $119.1M | $118.2M |
股东权益CATYOFIX
| Q4 25 | $2.9B | $450.0M | ||
| Q3 25 | $2.9B | $442.5M | ||
| Q2 25 | $2.9B | $458.3M | ||
| Q1 25 | $2.9B | $458.3M | ||
| Q4 24 | $2.8B | $503.1M | ||
| Q3 24 | $2.8B | $525.9M | ||
| Q2 24 | $2.8B | $546.0M | ||
| Q1 24 | $2.8B | $570.3M |
总资产CATYOFIX
| Q4 25 | $24.2B | $850.6M | ||
| Q3 25 | $24.1B | $832.6M | ||
| Q2 25 | $23.7B | $837.2M | ||
| Q1 25 | $23.2B | $823.1M | ||
| Q4 24 | $23.1B | $893.3M | ||
| Q3 24 | $23.3B | $867.9M | ||
| Q2 24 | $23.2B | $882.0M | ||
| Q1 24 | $23.4B | $906.0M |
负债/权益比CATYOFIX
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | 0.36× | ||
| Q2 25 | 0.04× | 0.34× | ||
| Q1 25 | 0.04× | 0.34× | ||
| Q4 24 | 0.04× | 0.31× | ||
| Q3 24 | 0.04× | 0.23× | ||
| Q2 24 | 0.04× | 0.22× | ||
| Q1 24 | 0.04× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $368.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $363.7M | $16.8M |
| 自由现金流率自由现金流/营收 | 163.2% | 7.6% |
| 资本支出强度资本支出/营收 | 2.2% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.07× | — |
| 过去12个月自由现金流最近4个季度 | $672.7M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CATYOFIX
| Q4 25 | $368.6M | $27.7M | ||
| Q3 25 | $150.6M | $12.4M | ||
| Q2 25 | $64.0M | $11.6M | ||
| Q1 25 | $99.0M | $-18.4M | ||
| Q4 24 | $329.2M | $23.7M | ||
| Q3 24 | $81.2M | $11.7M | ||
| Q2 24 | $72.9M | $9.0M | ||
| Q1 24 | $88.2M | $-18.6M |
自由现金流CATYOFIX
| Q4 25 | $363.7M | $16.8M | ||
| Q3 25 | $150.1M | $2.5M | ||
| Q2 25 | $62.7M | $4.5M | ||
| Q1 25 | $96.3M | $-25.1M | ||
| Q4 24 | $325.5M | $15.2M | ||
| Q3 24 | $80.0M | $6.3M | ||
| Q2 24 | $72.4M | $-360.0K | ||
| Q1 24 | $87.3M | $-29.1M |
自由现金流率CATYOFIX
| Q4 25 | 163.2% | 7.6% | ||
| Q3 25 | 71.3% | 1.2% | ||
| Q2 25 | 31.9% | 2.2% | ||
| Q1 25 | 51.2% | -13.0% | ||
| Q4 24 | 174.6% | 7.0% | ||
| Q3 24 | 42.2% | 3.2% | ||
| Q2 24 | 40.5% | -0.2% | ||
| Q1 24 | 49.8% | -15.4% |
资本支出强度CATYOFIX
| Q4 25 | 2.2% | 4.9% | ||
| Q3 25 | 0.2% | 4.8% | ||
| Q2 25 | 0.6% | 3.5% | ||
| Q1 25 | 1.4% | 3.5% | ||
| Q4 24 | 1.9% | 4.0% | ||
| Q3 24 | 0.6% | 2.7% | ||
| Q2 24 | 0.3% | 4.7% | ||
| Q1 24 | 0.5% | 5.6% |
现金转化率CATYOFIX
| Q4 25 | 4.07× | — | ||
| Q3 25 | 1.94× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 1.42× | — | ||
| Q4 24 | 4.10× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.09× | — | ||
| Q1 24 | 1.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CATY
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
